In a closed Forum in UK a guy who pretends to be an ex Janssen (from his comments covering the Pharma-Sector it sounds credible) talked about a settlemend offer figure which was clearly higher than the present capitalisation.
Whatever the range then would be is open to debate and why he would know this of course as well. But one Thing I learned in life: there are no secrets within corporation channels which would not find a way outside of the room. But then the same guy wrote, that some big shareholders gave word (Support) to the Company not to accept the offer and they would back them. Well, this Statement I would Support, as a Management usually cannot ignore the voice from large shareholders.
If so; then those shareholders who have a certain Portion invested in the Company may be of the belief, that over time DECN could get much more Money out of a Settlement on one Hand and on the other Hand must see a big potential ahead for DECN if and when the execution of their plans starts.
I would then say, that this part of the press-release may present what they could have in mind.
The company, more importantly, is announcing that the preparation for an expected explosion of product demand following legal victory has already begun. Solicitations for interview and quotation have been circulated to various internationally certified and FDA approved manufacturers for the contract manufacture of GenStrip™ 50. The time frame for tooling creation, first article part delivery and full product production is expected to fall within a five to seven month timeframe, following the final selection of an international contract manufacturer. Concurrent to the fulfillment of supplemental GenStrip™ 50 manufacturing, that selected manufacturer will simultaneously be charged with the completion of a new product that has been under internal development for nearly a year. Several of these manufacturing candidates are currently manufacturing second generation, FDA cleared, embryonic versions of the company's (3rd generation) product concept.
